Should you continue to rely on Emergent Biosolutions (USA Stocks:EBS) management?

All Stories . Forecast . 
Aina Ster .  Story
EBS Stock  USD 13.73  0.24  1.72%   
Aina Ster
By Aina Ster
Macroaxis Story
Emergent Biosolutions Working Capital is relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Working Capital of 1.03 Billion. As of 01/08/2023, Interest Coverage is likely to grow to 13.52, while Revenue Per Employee is likely to drop slightly above 594.6 K. The primary reasoning behind this post is to break down Emergent potential for February. We are going to discuss if Emergent Biosolutions is reasonably priced going into February.
Published over three weeks ago
View all stories for Emergent Biosolutions | View All Stories
Over 85.0% of Emergent Biosolutions shares are held by institutions such as insurance companies. Institutional ownership of Emergent Biosolutions refers to the amount of Emergent Biosolutions equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Emergent, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Emergent Biosolutions. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Emergent Biosolutions

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Emergent Biosolutions' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Emergent Biosolutions in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
6 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Emergent Biosolutions. Your research has to be compared to or analyzed against Emergent Biosolutions' peers to derive any actionable benefits. When done correctly, Emergent Biosolutions' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Emergent Biosolutions.

How important is Emergent Biosolutions's Liquidity

Emergent Biosolutions financial leverage refers to using borrowed capital as a funding source to finance Emergent Biosolutions ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Emergent Biosolutions financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Emergent Biosolutions's total debt and its cash.

How does Emergent utilize its cash?

To perform a cash flow analysis of Emergent Biosolutions, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Emergent Biosolutions is receiving and how much cash it distributes out in a given period. The Emergent Biosolutions cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Emergent Biosolutions Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Emergent Biosolutions reported Net Cash Flow from Operations of 288.99 Million in 2022

Breaking down Emergent Biosolutions Further

The latest fall in stock price could raise concerns from retail investors as the firm is trading at a share price of 13.56 on very low momentum in volume. The company executives have failed to build on market volatilities in December. However, diversifying your overall positions with Emergent Biosolutions may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.2. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Emergent Biosolutions partners.

Returns Breakdown

Return on Investment11.74
Return on Assets6.41
Return on Equity11.43
Return Capital0.18
Return on Sales0.22

Emergent Biosolutions implied volatility may change after the spike

Value At Risk just dropped to -6.47, may connote upcoming price depreciation. Emergent Biosolutions is displaying above-average volatility over the selected time horizon. Investors should scrutinize Emergent Biosolutions independently to ensure intended market timing strategies are aligned with expectations about Emergent Biosolutions volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Emergent Biosolutions' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Emergent Biosolutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Emergent Biosolutions

While some firms in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Emergent may not be as strong as the others in terms of longer-term growth potentials. All things considered, as of the 8th of January 2023, our latest 90 days advice on the enterprise is Hold. We believe Emergent Biosolutions is undervalued with close to average probability of bankruptcy for the next two years.

Editorial Staff

Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Emergent Biosolutions. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY